Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo + PPI Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

NCT01209104
View directory record Official record
Conditions
Nutritional Status
Interventions
GSK1325756
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 2 Interventional

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

NCT02030925
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
IW-3718, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
North Little Rock, Arkansas • Anaheim, California • Monroe, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

NCT01155284
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sitagliptin and Lansoprazole, Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
11 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gastric Acid Suppression and Probiotic Colonization

NCT03327051
View directory record Official record
Conditions
Probiotics
Interventions
Omeprazole, VSL #3, Placebo
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers

NCT04984525
View directory record Official record
Conditions
Healthy
Interventions
SYNB1934, SYNB1618
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 28, 2026, 7:21 AM EDT
Not listed Phase 4 Interventional

Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy

NCT01328652
View directory record Official record
Conditions
Laryngopharyngeal Reflux, Hypertrophy of Lingual Tonsil
Interventions
dexlansoprazole
Drug
Lead sponsor
Advanced Center for Specialty Care
Other
Eligibility
18 Years to 59 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 3 Interventional

The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux

NCT00324974
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Lansoprazole microgranules suspension, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Sep 28, 2026, 7:21 AM EDT
Not listed Phase 2 Interventional

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

NCT05449444
View directory record Official record
Conditions
Mast Cell Activation Syndrome
Interventions
Masitinib 4.5 mg/kg/day, Placebo, Best supportive care, Masitinib 6.0 mg/kg/day
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Weldon Spring, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 28, 2026, 7:21 AM EDT
Terminated Phase 2 Interventional Results available

Fexofenadine Use in Gastroesophageal Reflux Symptoms

NCT03425097
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Fexofenadine, Placebo - Cap
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 28, 2026, 7:21 AM EDT
Withdrawn Not applicable Interventional

PPI Versus Placebo in Severe Functional Heartburn

NCT00222989
View directory record Official record
Conditions
GERD
Interventions
PPI
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2100
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 4 Interventional Results available

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

NCT02708355
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 28, 2026, 7:21 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907
View directory record Official record
Conditions
Weight Management
Interventions
GS-4571, Placebo, Omeprazole
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Not applicable Interventional Results available

Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study

NCT01136980
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Hiatal Hernia
Interventions
TIF Transoral Fundoplication, Sham placebo procedure
Device · Other
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Englewood, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 28, 2026, 7:21 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

NCT05998863
View directory record Official record
Conditions
Osteoporosis, Hypomagnesemia
Interventions
EffCaMgCit, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

NCT01043185
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
AZD3355, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gastric pH and Anthocyanin Absorption

NCT01122160
View directory record Official record
Conditions
Anthocyanin Metabolism
Interventions
omeprazole, placebo
Drug
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
22 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 28, 2026, 7:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

NCT05517928
View directory record Official record
Conditions
Healthy
Interventions
Omeprazole, Lactobacillus rhamnosus GG, Placebo
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI

NCT01005251
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Heartburn, Regurgitation
Interventions
lesogaberan (AZD3355), Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Sep 28, 2026, 7:21 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery

NCT06488001
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
pantoprazole, Placebo
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 79 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 2 Interventional

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

NCT05556824
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
MHS-1031, Placebo
Drug · Other
Lead sponsor
Microbiome Health Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Lake City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 28, 2026, 7:21 AM EDT
Terminated Phase 4 Interventional Results available

Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness

NCT00637416
View directory record Official record
Conditions
Dysphonia
Interventions
Lansoprazole, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
3 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 28, 2026, 7:21 AM EDT
Recruiting Phase 2 Interventional

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT05996627
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil, Biospecimen Collection, Electronic Health Record Review, Placebo Administration
Drug · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Duarte, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 28, 2026, 7:21 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 28, 2026, 7:21 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux

NCT00369265
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Lansoprazole, Sugar pill
Drug · Dietary Supplement
Lead sponsor
American Institute for Voice and Ear Research
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 28, 2026, 7:21 AM EDT